Physician profile
Lisa C Moore
NPI 1386801710
$4,744.98
in general payments reported to CMS, 2019-2025
28 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $437 · 2021: $176 · 2022: $438 · 2023: $762 · 2024: $664 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Education: $46.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.05 |
| Education | $46.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $793.01 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $569.92 | 2019-2023 | |
| Lilly USA, LLC | $547.39 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $439.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.45 | 2022-2023 | Jardiance, Ofev, Synjardy |
| Abbott Laboratories | $266.67 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $197.40 | 2019-2020 | |
| Mannkind Corporation | $184.47 | 2019-2025 | |
| Amgen INC. | $177.75 | 2019 | |
| Corcept Therapeutics | $176.08 | 2019-2023 | Korlym |
| Valeritas, INC. | $172.65 | 2019 | |
| Shire North American Group INC | $131.46 | 2019 | |
| Gilead Sciences, INC. | $119.71 | 2024 | Descovy |
| Regeneron Healthcare Solutions, INC. | $117.15 | 2023 | Dupixent |
| Dexcom, INC. | $103.24 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $100.31 | 2019-2022 | |
| Allergan, INC. | $70.41 | 2021 | |
| Medtronic Minimed, INC. | $57.19 | 2020 | |
| Amag Pharmaceuticals, INC. | $37.12 | 2019 | |
| Medtronic, INC. | $36.03 | 2021-2022 | |
| Beta Bionics, INC. | $35.86 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $28.04 | 2023 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $26.77 | 2023 | Nucala |
| Tandem Diabetes Care, INC. | $21.55 | 2019 | |
| Senseonics, Incorporated | $20.00 | 2020 | |
| Radius Health, INC. | $14.52 | 2024 | Tymlos |
| Lupin INC. | $13.54 | 2019 | |
| Therapeuticsmd, INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.